These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 20826181)

  • 41. Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.
    Zorrilla EP; Heilig M; de Wit H; Shaham Y
    Drug Alcohol Depend; 2013 Mar; 128(3):175-86. PubMed ID: 23294766
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of corticotropin-releasing factor pathways in stress-related alterations of colonic motor function and viscerosensibility in female rodents.
    Taché Y; Million M; Nelson AG; Lamy C; Wang L
    Gend Med; 2005 Sep; 2(3):146-54. PubMed ID: 16290887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain.
    Hubbard CS; Labus JS; Bueller J; Stains J; Suyenobu B; Dukes GE; Kelleher DL; Tillisch K; Naliboff BD; Mayer EA
    J Neurosci; 2011 Aug; 31(35):12491-500. PubMed ID: 21880911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.
    Li YW; Fitzgerald L; Wong H; Lelas S; Zhang G; Lindner MD; Wallace T; McElroy J; Lodge NJ; Gilligan P; Zaczek R
    CNS Drug Rev; 2005; 11(1):21-52. PubMed ID: 15867951
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell type-specific modifications of corticotropin-releasing factor (CRF) and its type 1 receptor (CRF1) on startle behavior and sensorimotor gating.
    Flandreau E; Risbrough V; Lu A; Ableitner M; Geyer MA; Holsboer F; Deussing JM
    Psychoneuroendocrinology; 2015 Mar; 53():16-28. PubMed ID: 25575243
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.
    Chaki S; Nakazato A; Kennis L; Nakamura M; Mackie C; Sugiura M; Vinken P; Ashton D; Langlois X; Steckler T
    Eur J Pharmacol; 2004 Feb; 485(1-3):145-58. PubMed ID: 14757135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology.
    Bangasser DA; Curtis A; Reyes BA; Bethea TT; Parastatidis I; Ischiropoulos H; Van Bockstaele EJ; Valentino RJ
    Mol Psychiatry; 2010 Sep; 15(9):877, 896-904. PubMed ID: 20548297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacology of anxiolytics and antidepressants: a psychopharmacological perspective.
    Nutt DJ; Glue P
    Pharmacol Ther; 1989; 44(3):309-34. PubMed ID: 2577512
    [No Abstract]   [Full Text] [Related]  

  • 49. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress.
    Gutman DA; Owens MJ; Skelton KH; Thrivikraman KV; Nemeroff CB
    J Pharmacol Exp Ther; 2003 Feb; 304(2):874-80. PubMed ID: 12538845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSD.
    Adamec R; Fougere D; Risbrough V
    Int J Neuropsychopharmacol; 2010 Jul; 13(6):747-57. PubMed ID: 19751543
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G
    J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic activation of NPFFR2 stimulates the stress-related depressive behaviors through HPA axis modulation.
    Lin YT; Liu TY; Yang CY; Yu YL; Chen TC; Day YJ; Chang CC; Huang GJ; Chen JC
    Psychoneuroendocrinology; 2016 Sep; 71():73-85. PubMed ID: 27243477
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Substance P antagonists: meet the new drugs, same as the old drugs? Insights from transgenic animal models.
    Santarelli L; Saxe MD
    CNS Spectr; 2003 Aug; 8(8):589-96. PubMed ID: 12907922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistent anxiolytic affects after chronic administration of the CRF₁ receptor antagonist R121919 in rats.
    Gutman DA; Owens MJ; Thrivikraman KV; Nemeroff CB
    Neuropharmacology; 2011 Jun; 60(7-8):1135-41. PubMed ID: 20951149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors.
    Hummel M; Cummons T; Lu P; Mark L; Harrison JE; Kennedy JD; Whiteside GT
    Neuropharmacology; 2010 Sep; 59(3):160-6. PubMed ID: 20470804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SSRI or CRF antagonism partially ameliorate depressive-like behavior after adolescent social defeat.
    Bourke CH; Glasper ER; Neigh GN
    Behav Brain Res; 2014 Aug; 270():295-9. PubMed ID: 24867331
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The CRF1 and the CRF2 receptor mediate recognition memory deficits and vulnerability induced by opiate withdrawal.
    Morisot N; Contarino A
    Neuropharmacology; 2016 Jun; 105():500-507. PubMed ID: 26907806
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders.
    Grigoriadis DE
    Expert Opin Ther Targets; 2005 Aug; 9(4):651-84. PubMed ID: 16083336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?
    Griebel G
    Pharmacol Ther; 1999 Apr; 82(1):1-61. PubMed ID: 10341356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vasopressin antagonists as anxiolytics and antidepressants: recent developments.
    Simon NG; Guillon C; Fabio K; Heindel ND; Lu SF; Miller M; Ferris CF; Brownstein MJ; Garripa C; Koppel GA
    Recent Pat CNS Drug Discov; 2008 Jun; 3(2):77-93. PubMed ID: 18537767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.